# Nucleus: Q2 Update | Nucleus

- Canonical URL: https://wefunder.com/feed/174540
- Entity ID: wefunder:feed_item:174540
- Published at: 2024-07-12 16:39:01 UTC
- Updated at: 2025-07-18 14:07:30 UTC

## Author
Logan Lenz

## Subject
Nucleus

## Content
Nucleus family,Another quarter is in the books and Nucleus continues to prosper despite all of the uncertainty surrounding it. We've maintained focus on staying lean and generating revenue in order to extend our runway so that we can continue to support the psychedelics industry for as long as possible. I know I keep referencing our goals in these updates, but it's important to understand how we're looking at the health of Nucleus. That's why I'll continue to call out the 4 core main objectives listed below:Generate as much revenue as possible.Reduce costs to meet revenue (as close to break even as possible).Extend runway (to ensure 18-24 months of operations).Innovate with the industry.So, how did we do in Q2? Let's take a closer look. Over $30K in Billed RevenueOur MRR has been nudging up and since May, we entered into our largest client deal to date. This put us closer to $11K in revenue per month. I'm pleased to say that the relationship is going well so far and we're hoping months 2 and 3 exceed expectations so we can squeeze even more revenue out of not only the relationship, but the model as a whole. Reducing CostsIn a perfect world, our monthly expenses would forcibly match our revenue to eliminate burn. Our burn remains $4K-5K but positioned to be reduced with our gradually increasing revenue. I'm always investigating new ways to reduce costs just to be cautious, but I'm keeping everything as close to $15K per month for the time being. Runway Has Been ExtendingWith less than $5K of monthly burn, our runway has extended into 2027. We know how important it is for Nucleus to stick around for as long as possible, which is why we continue to reiterate this as a key metric for the company during this time. InnovateOur focus on new client relationships have us unpacking a broader servicing arm for clinical trial recruitment. During Q3, we plan to look deeper into targeting trials outside of solely psychedelics. We are already in talks with trials involving smoking cessation and cannabis. While not a priority, there are still a myriad of outstanding projects we will continue to look at throughout the remainder of the year.Neuly AIPsychedelic Invest 3.0 (Redesign and Content Upgrades)A Blockchain Product (Particles 2.0)AI-Based Medical Billing SolutionWe're also looking into taking a step back from being known as a 'venture studio' and using the infrastructure we've established to offer development services to startups looking to build and/or maintain their tech stacks. Nucleus' Ecosystem GrowthOverall traffic slowed in Q2 compared to previous periods. That said, our ecosystem does continue to expand, albeit slower than usual. Neuly users increased 3%Psychedelic Invest subscribers elevated 16%Video views increased 3%Podcast listens rose 8%We'll have to see how the industry performs in Q3. If traffic continues to dwindle, we will be sure to level up our new user acquisition strategy in more creative ways.Content CreationBelow is a review of all published content in Q2. To save time, I won't link to all of them - just the latest posts from the month of June. Press Releases: 142 39 in JuneOriginal Articles and Events: 42 11 in JuneProposal to Approve MDMA for PTSD Treatment FailsEffective Psychedelic Treatment for Long-COVID Symptoms: A Case StudyPsychedelic Retreats Market Set to Cross $1 Trillion By 2027UC Berkeley’s Groundbreaking Study Exploring Psilocybin’s Effects on PerceptionLykos Therapeutics Addresses Concerns Over MDMA Treatment for PTSDWhat Mindbloom’s Ketamine Study Could Mean for the Psychedelics IndustryPsychedelic Legislative Trends in 2024: A Detailed OverviewPsychedelics and Their Potential to Alleviate Death AnxietyHow Might Psychedelics Help With Stuttering?Mexico Might Be Legalizing Magic MushroomsThe Therapeutic Potential of Psychedelics in Brain Health and AgingHere's To More Growth in 2024!While the industry we predominantly operate in remains murky, Nucleus continues to sit in a strong position to expand beyond it. We'll keep looking for new opportunities, interesting deals, and more revenue opportunities in order to keep the fight alive for as long as we possibly can. Thank you for your continued support along this journey. We could not do this work without all of our investors. If you ever have any questions ideas, concerns, or comments, please reach out to me directly at logan@withnucleus.com.Let's continue to change the world!